Background: Hybrid aortic arch reconstruction represents a treatment option for patients unsuitable for conventional open cardiovascular surgery. We analyzed patient outcome after hemiarch repair in zone 1 and zone 2 with regard to early and long-term results.
Methods: Between December 2004 and December 2012, a total of 47 patients underwent hemiarch repair for distal aortic arch disease. Supra-aortic debranching was performed in 23 patients for zone 1 (carotid-carotid crossover bypass) and in 24 patients for zone 2 (carotid-subclavian bypass/subclavian transposition) followed by thoracic endovascular aortic repair. All patients included had been refused for open surgery or were emergency cases.
Results: Mean age of the patients was 65.3 years; 51% of patients were symptomatic or presented with a contained aortic rupture. Overall technical success rate was 81%, with a 30-day mortality rate of 12.8%. A primary type Ia endoleak was observed in 19%. The mean follow-up period was 50.5 months (range, 1-93 months). Follow-up mortality was 14.9%; secondary endoleak rate was 8.5% for both groups. There was a trend of reduced primary type Ia endoleak rate for zone 2 repair compared with zone 1 (4.3% vs 14.9%; P = .07). Follow-up mortality was also improved for zone 2 repair (4.3% vs 10.6%; P = .41). Overall survival rate was 70%.
Conclusions: Hemiarch hybrid repair in high-risk patients is associated with an acceptable perioperative mortality risk and long-term survival. Zone 2 represents a feasible and effective treatment option for hybrid arch repair. Zone 1 is related with relevant risk for type Ia endoleak and higher mortality during follow-up. Lifelong surveillance after hybrid repair is essential.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvs.2015.05.004 | DOI Listing |
J Vasc Surg Cases Innov Tech
April 2025
Department of Radiology and Nuclear Medicine, University Teaching and Research Hospital Lucerne, Luzern, Switzerland.
Objective: The aim of this single-center case series is to demonstrate that an ultra-low dose (ULD) can be routinely achieved in the hybrid operating room in standard endovascular aortic repair (EVAR) for infrarenal abdominal aortic aneurysm by adjusting the manufacturer's predefined imaging parameters, hardware configurations and user protocols (including benchmarking).
Methods: The hybrid operating room manufacturer predefined EVAR software setup of the dose exposure control software (OPTIQ, Siemens Healthineers, Forchheim, Germany) at our university medical center was screened for possible improvements regarding radiation dose application. Tests on a water-equivalent as well as polymethyl methacrylate phantom model to assess the impact of technical settings were performed, including comparison of settings for exposure control software, different magnification, collimation configurations and detector distance.
Carbohydr Polym
March 2025
College of Bioresources Chemical and Materials Engineering, Shaanxi University of Science and Technology, Shaanxi Provincial Key Laboratory of Papermaking Technology and Specialty Paper Development, Key Laboratory of Paper Based Functional Materials of China National Light Industry, National Demonstration Center for Experimental Light Chemistry Engineering Education, Xi'an 710021, China.
Current conventional wound dressings used for wound healing are often characterized by restricted bioactivity and devoid of multifunctionality resulting in suboptimal treatment and prolonged healing. Despite recent advances, the simultaneous incorporation of excellent flexibility, good mechanical performance, self-healing, bioactivity, and adhesion properties into the dressings without complicating their efficacy while maintaining simple synthesis remains a grand challenge. Herein, we effectively synthesized hybrid hydrogels of cellulose nanofiber (CNF), polyvinyl alcohol (PVA), and curcumin-modified silver nanoparticles (cAg) through a one-step synthesis method based on hydrogen bonds, dynamic boronic ester bonds, and coordinate covalent bonds.
View Article and Find Full Text PDFSci Rep
January 2025
Emergency department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Esophageal squamous cell carcinoma (ESCC) is one of the most common digestive malignancies. Our previous studies revealed necroptosis-related lncRNA ENSG00000253385.1 was an independent prognostic factor for ESCC.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
Department of Radiology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, 305 East Zhongshan Road, Nanjing, 210002, China.
Pyroptosis is a key mode of programmed cell death during the early stages following acute myocardial infarction (AMI), driving immune-inflammatory responses. Cardiac resident macrophages (CRMs) are the primary mediators of cardiac immunity, and they serve a dual role through their shaping of both myocardial injury and post-AMI myocardial repair. To appropriately regulate AMI-associated inflammation, HM4oRL is herein designed, an innovative bifunctional therapeutic nanoplatform capable of inhibiting cardiomyocyte pyroptosis while reprogramming inflammatory signaling.
View Article and Find Full Text PDFEur Heart J
January 2025
School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 2199 Lishui Rd, Nanshan, Shenzhen, Guangdong Province 518055, China.
Background And Aims: Lackluster results from recently completed gene therapy clinical trials of VEGF-A delivered by viral vectors have heightened the need to develop alternative delivery strategies. This study aims to demonstrate the pre-clinical efficacy and safety of extracellular vesicles (EVs) loaded with VEGF-A mRNA for the treatment of ischaemic vascular disease.
Methods: After encapsulation of full-length VEGF-A mRNA into fibroblast-derived EVs via cellular nanoporation (CNP), collected VEGF-A EVs were delivered into mouse models of ischaemic injury.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!